{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:25:33Z","timestamp":1791026733998,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1124\/dmd.106.010132","type":"journal-article","created":{"date-parts":[[2006,7,13]],"date-time":"2006-07-13T00:44:46Z","timestamp":1152751486000},"page":"1742-1748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction"],"prefix":"10.1016","volume":"34","author":[{"given":"Sharon L.","family":"Ripp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odette A.","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Trevena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Liras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"de Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.106.010132_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0010-7824(80)90102-X","article-title":"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.","volume":"22","author":"Back","year":"1980","journal-title":"Contraception"},{"key":"10.1124\/dmd.106.010132_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam.","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.010132_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.","volume":"37","author":"Backman","year":"1996","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.106.010132_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers Of America (PhRMA) perspective.","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2125.1990.tb05457.x","article-title":"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.","volume":"30","author":"Crawford","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib6","first-page":"1325","article-title":"Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes.","volume":"29","author":"Drocourt","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib7","first-page":"1499","article-title":"Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers.","volume":"29","author":"El-Sankary","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib8","first-page":"1329","article-title":"The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.","volume":"56","author":"Goodwin","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.010132_bib10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/0024-3205(90)90431-P","article-title":"Metabolism of 17 alpha-ethynylestradiol in humans.","volume":"47","author":"Guengerich","year":"1990","journal-title":"Life Sci"},{"key":"10.1124\/dmd.106.010132_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/009127009903901112","article-title":"Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.","volume":"39","author":"Harris","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1472-8206.1991.tb00711.x","article-title":"Lack of effect by nifedipine on hepatic mixed function oxidase in man.","volume":"5","author":"Horsmans","year":"1991","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/00912700122010456","article-title":"Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.","volume":"41","author":"Inglis","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1124\/dmd.106.010132_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0090-9556(25)06553-5","article-title":"Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.","volume":"23","author":"Kocarek","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0090-9556(24)13663-X","article-title":"Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin.","volume":"28","author":"Ledirac","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Investig"},{"key":"10.1124\/dmd.106.010132_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","article-title":"Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.","volume":"107","author":"Li","year":"1997","journal-title":"Chem-Biol Interact"},{"key":"10.1124\/dmd.106.010132_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00912709922007985","article-title":"Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.","volume":"39","author":"Loi","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","article-title":"Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.","volume":"31","author":"Madan","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/00498258309052280","article-title":"The biliary and urinary metabolites of [3H]17 alpha-ethynylestradiol in women.","volume":"13","author":"Maggs","year":"1983","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.010132_bib25","article-title":"Use of midazolam and fexofenadine to assess induction of cytochrome P4503A4 and P-glycoprotein in humans.","volume":"6","author":"McRobie","year":"2004","journal-title":"AAPS J"},{"key":"10.1124\/dmd.106.010132_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.103.061713","article-title":"Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line.","volume":"309","author":"Mills","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.010132_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0026-895X(25)09239-9","article-title":"Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes.","volume":"41","author":"Pichard","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.106.010132_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/dmd.31.5.533","article-title":"Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.","volume":"31","author":"Raucy","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0009-2797(99)00089-7","article-title":"Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.","volume":"121","author":"Reinach","year":"1999","journal-title":"Chem-Biol Interact"},{"key":"10.1124\/dmd.106.010132_bib30","first-page":"409","article-title":"Lack of drug-drug interaction between cerivastatin and nifedipine.","volume":"36","author":"Sachse","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.010132_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/dmd.31.4.439","article-title":"Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.","volume":"31","author":"Sahi","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.010132_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/jpet.103.050526","article-title":"Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.","volume":"306","author":"Sahi","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.010132_bib33","series-title":"Xenotechniques","first-page":"1","article-title":"Immortalized hepatocytes: a new in vitro approach to enzyme induction studies","author":"Xenotech","year":"2003"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624036298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624036298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.106.010132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:10:26Z","timestamp":1739902226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624036298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0090955624036298"],"URL":"https:\/\/doi.org\/10.1124\/dmd.106.010132","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.106.010132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}